China Traditional Chinese Medicine Holdings Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
China Traditional Chinese Medicine Holdings wird ein jährliches Gewinn- und Umsatzwachstum von 12.3% bzw. 16.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 12.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.5% betragen.
Wichtige Informationen
10.5%
Wachstumsrate der Gewinne
11.4%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 10.6% |
| Wachstumsrate der Einnahmen | 16.7% |
| Zukünftige Eigenkapitalrendite | 11.5% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 28 May 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
China Traditional Chinese Medicine Holdings Co. Limited's (HKG:570) P/E Still Appears To Be Reasonable
Jan 04
Is China Traditional Chinese Medicine Holdings (HKG:570) Using Too Much Debt?
Oct 23Calculating The Intrinsic Value Of China Traditional Chinese Medicine Holdings Co. Limited (HKG:570)
Aug 23Is China Traditional Chinese Medicine Holdings (HKG:570) Using Too Much Debt?
May 22China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) Analysts Are Reducing Their Forecasts For This Year
Dec 08These 4 Measures Indicate That China Traditional Chinese Medicine Holdings (HKG:570) Is Using Debt Extensively
Sep 05China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) Analysts Just Cut Their EPS Forecasts Substantially
Jul 20Calculating The Fair Value Of China Traditional Chinese Medicine Holdings Co. Limited (HKG:570)
Jul 18Here's Why I Think China Traditional Chinese Medicine Holdings (HKG:570) Is An Interesting Stock
Jun 01Here's Why China Traditional Chinese Medicine Holdings (HKG:570) Can Manage Its Debt Responsibly
Apr 28Calculating The Fair Value Of China Traditional Chinese Medicine Holdings Co. Limited (HKG:570)
Feb 14Here's Why I Think China Traditional Chinese Medicine Holdings (HKG:570) Is An Interesting Stock
Jan 11Here's Why China Traditional Chinese Medicine Holdings (HKG:570) Can Manage Its Debt Responsibly
Dec 05China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) Shares Could Be 27% Below Their Intrinsic Value Estimate
Oct 29I Ran A Stock Scan For Earnings Growth And China Traditional Chinese Medicine Holdings (HKG:570) Passed With Ease
Oct 11These 4 Measures Indicate That China Traditional Chinese Medicine Holdings (HKG:570) Is Using Debt Reasonably Well
Aug 24Is Now The Time To Put China Traditional Chinese Medicine Holdings (HKG:570) On Your Watchlist?
Jul 13China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) Shares Could Be 46% Below Their Intrinsic Value Estimate
Jun 25Does China Traditional Chinese Medicine Holdings (HKG:570) Deserve A Spot On Your Watchlist?
Apr 04Are Investors Undervaluing China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) By 30%?
Mar 15China Traditional Chinese Medicine Holdings Co. Limited's (HKG:570) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Feb 22China Traditional Chinese Medicine Holdings (HKG:570) Shareholders Have Enjoyed A 19% Share Price Gain
Feb 01What Percentage Of China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) Shares Do Insiders Own?
Dec 18Is China Traditional Chinese Medicine Holdings Co. Limited (HKG:570) Trading At A 33% Discount?
Dec 03
Declining Stock and Decent Financials: Is The Market Wrong About China Traditional Chinese Medicine Holdings Co. Limited (HKG:570)?
Nov 18Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 30,738 | 1,851 | N/A | N/A | 2 |
| 12/31/2025 | 25,494 | 1,485 | N/A | 3,011 | 3 |
| 12/31/2024 | 22,357 | 1,358 | N/A | 1,896 | 3 |
| 12/31/2023 | 18,122 | 1,285 | 680 | 1,169 | N/A |
| 9/30/2023 | 17,909 | 1,107 | 174 | 695 | N/A |
| 6/30/2023 | 17,696 | 929 | -332 | 222 | N/A |
| 3/31/2023 | 16,000 | 847 | 117 | 657 | N/A |
| 12/31/2022 | 14,304 | 764 | 566 | 1,092 | N/A |
| 9/30/2022 | 15,560 | 1,091 | 512 | 1,119 | N/A |
| 6/30/2022 | 16,815 | 1,417 | 458 | 1,146 | N/A |
| 3/31/2022 | 17,934 | 1,675 | 188 | 971 | N/A |
| 12/31/2021 | 19,053 | 1,933 | -81 | 796 | N/A |
| 9/30/2021 | 17,677 | 1,897 | 374 | 1,372 | N/A |
| 6/30/2021 | 16,300 | 1,861 | 829 | 1,948 | N/A |
| 3/31/2021 | 15,553 | 1,762 | -73 | 1,088 | N/A |
| 12/31/2020 | 14,806 | 1,663 | -975 | 228 | N/A |
| 9/30/2020 | 14,423 | 1,562 | -334 | 723 | N/A |
| 6/30/2020 | 14,039 | 1,461 | 308 | 1,218 | N/A |
| 3/31/2020 | 14,180 | 1,525 | 477 | 1,401 | N/A |
| 12/31/2019 | 14,321 | 1,588 | 646 | 1,585 | N/A |
| 9/30/2019 | 13,528 | 1,563 | 237 | 1,341 | N/A |
| 6/30/2019 | 12,735 | 1,538 | -173 | 1,097 | N/A |
| 3/31/2019 | 11,997 | 1,488 | 26 | 1,144 | N/A |
| 12/31/2018 | 11,259 | 1,439 | 224 | 1,190 | N/A |
| 9/30/2018 | 10,579 | 1,386 | 326 | 1,103 | N/A |
| 6/30/2018 | 9,900 | 1,332 | 428 | 1,016 | N/A |
| 3/31/2018 | 9,119 | 1,251 | 530 | 1,126 | N/A |
| 12/31/2017 | 8,338 | 1,170 | 633 | 1,236 | N/A |
| 9/30/2017 | 7,785 | 1,123 | N/A | 419 | N/A |
| 6/30/2017 | 7,233 | 1,075 | N/A | -397 | N/A |
| 3/31/2017 | 6,883 | 1,021 | N/A | 534 | N/A |
| 12/31/2016 | 6,533 | 967 | N/A | 1,465 | N/A |
| 9/30/2016 | 6,010 | 880 | N/A | 1,248 | N/A |
| 6/30/2016 | 5,487 | 794 | N/A | 1,031 | N/A |
| 3/31/2016 | 4,598 | 670 | N/A | 775 | N/A |
| 12/31/2015 | 3,709 | 546 | N/A | 519 | N/A |
| 9/30/2015 | 3,271 | 509 | N/A | N/A | N/A |
| 6/30/2015 | 2,833 | 471 | N/A | 397 | N/A |
| 3/31/2015 | 2,742 | 444 | N/A | 361 | N/A |
| 12/31/2014 | 2,650 | 417 | N/A | 325 | N/A |
| 9/30/2014 | 2,384 | 370 | N/A | N/A | N/A |
| 6/30/2014 | 2,117 | 324 | N/A | 176 | N/A |
| 3/31/2014 | 1,756 | 261 | N/A | 131 | N/A |
| 12/31/2013 | 1,395 | 198 | N/A | 85 | N/A |
| 9/30/2013 | 1,233 | 183 | N/A | 92 | N/A |
| 6/30/2013 | 1,082 | 170 | N/A | 101 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 570Das prognostizierte Gewinnwachstum (12.3% pro Jahr) liegt über der Sparquote (2.2%).
Ertrag vs. Markt: 570Die Erträge des Unternehmens (10.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Hong Kong (11.9% pro Jahr).
Hohe Wachstumserträge: 570Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: 570Die Einnahmen des Unternehmens (16.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.9% pro Jahr).
Hohe Wachstumseinnahmen: 570Die Einnahmen des Unternehmens (16.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 570Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.5 %).